← Back to Screener
ScreenerNewsCompareWatchlist
VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesNewsCompareWatchlist
AnalyzeValuationTotal ReturnDCA CalculatorInsider Activity

PLUR logoPluri Inc.(PLUR)Earnings, Financials & Key Ratios

PLUR•NASDAQ
$3.30
$209M mkt cap·Price updated May 6, 2026
SectorHealthcareIndustryBiotechnologySub-IndustryCell and Gene Therapy Developers
AboutPluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase II clinical trails for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as a solution for the treatment of acute radiation syndrome. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.Show more
  • Revenue$1M+309.8%
  • EBITDA-$22M+0.2%
  • Net Income-$23M-8.1%
  • EPS (Diluted)-3.56+10.8%
  • Gross Margin48.95%-50.4%
  • EBITDA Margin-1636.23%+75.6%
  • Operating Margin-1659.88%+75.6%
  • Net Margin-1690.34%+73.6%
  • ROE-992.66%-392.2%
  • ROIC-59.9%-22.7%
  • Interest Coverage-25.40+0.7%
Technical→

PLUR Key Insights

Pluri Inc. (PLUR) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

  • ✓Strong 5Y sales CAGR of 125.3%

✗Weaknesses

  • ✗Weak Piotroski F-Score: 2/9
  • ✗Negative free cash flow
  • ✗Shares diluted 100.0% in last year
  • ✗Trading more than 30% below 52-week high
  • ✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

PLUR Price & Volume

Pluri Inc. (PLUR) stock price & volume — 10-year historical chart

Loading chart...

PLUR Growth Metrics

Pluri Inc. (PLUR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years13.43%
5 Years125.33%
3 Years78.73%
TTM97.49%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM-34.69%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM6.99%

Return on Capital

10 Years-78.09%
5 Years-68.82%
3 Years-71.16%
Last Year-107.06%

PLUR Recent Earnings

Pluri Inc. (PLUR) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 3/12 qtrs (38%)●Beat Revenue 1/12 qtrs (14%)
Q1 2026Latest
Feb 12, 2026
EPS
$0.71
Est $0.65
-9.2%
Revenue
$198,000
Est $638,000
-69.0%
Q4 2025
Nov 12, 2025
EPS
$0.65
Est $0.74
+12.2%
Revenue
$316,000
Est $638,000
-50.5%
Q4 2025
Sep 17, 2025
EPS
$2.62
Est $0.65
-303.1%
Revenue
$398,000
Est $638,000
-37.6%
Q2 2025
May 13, 2025
EPS
$0.94
Est $0.73
-28.8%
Revenue
$427,000
Est $400,000
+6.8%
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q1 2026LatestFeb 12, 2026
$0.71vs $0.65-9.2%
$198,000vs $638,000-69.0%
Q4 2025Nov 12, 2025
$0.65vs $0.74+12.2%
$316,000vs $638,000-50.5%
Q4 2025Sep 17, 2025
$2.62vs $0.65-303.1%
$398,000vs $638,000-37.6%
Q2 2025May 13, 2025
$0.94vs $0.73-28.8%
$427,000vs $400,000+6.8%
Based on last 12 quarters of dataView full earnings history →

PLUR Peer Comparison

Pluri Inc. (PLUR) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison

Select Columns
Stock Universe
Valuation
Growth
Profitability
Financial Health
Dividends & Buybacks
Price Performance
Technical
Fundamentals ($)
Sector-Specific
CompanyMarket CapStock PriceP/E Ratio (TTM)Revenue Growth 1YNet MarginReturn on Equity (ROE)FCF YieldDebt / Equity
FATE logoFATEFate Therapeutics, Inc.Direct Competitor264.17M2.29-1.99-51.24%-20.51%-65.79%0.38
NTLA logoNTLAIntellia Therapeutics, Inc.Direct Competitor1.61B13.85-3.64-100%-61.47%0.14
BEAM logoBEAMBeam Therapeutics Inc.Direct Competitor3.32B32.33-39.92120.01%-57.24%-7.31%0.24
EDIT logoEDITEditas Medicine, Inc.Direct Competitor310.73M3.18-1.76-100%-5.23%0.66
CRSP logoCRSPCRISPR Therapeutics AGDirect Competitor5.31B55.08-8.51-89.97%-138.57%-30.88%0.21
IOVA logoIOVAIovance Biotherapeutics, Inc.Product Competitor1.68B4.09-3.7560.6%-148.38%-55.97%0.07
CELC logoCELCCelcuity Inc.Product Competitor6.03B139.44-49.27-179%0.85
RCKT logoRCKTRocket Pharmaceuticals, Inc.Product Competitor418.11M3.86-1.92-80.49%0.09

Compare PLUR vs Peers

Pluri Inc. (PLUR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs FATE

Most directly comparable listed peer for PLUR.

Scale Benchmark

vs TMO

Larger-name benchmark to compare PLUR against a more recognizable public peer.

Peer Set

Compare Top 5

vs FATE, NTLA, BEAM, EDIT

PLUR Income Statement

Pluri Inc. (PLUR) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily
Line itemJun'17Jun'18Jun'19Jun'20Jun'21Jun'22Jun'23Jun'24Jun'25TTM
Sales/Revenue050K54K23K0234K287K326K1.34M1.34M
Revenue Growth %-100%-8%-57.41%-100%-22.65%13.59%309.82%97.49%
Cost of Goods Sold2.18M2K2K1.57M1.37M1.05M9K4K682K795K
COGS % of Revenue-4%3.7%6826.09%-450%3.14%1.23%51.05%-
Gross Profit
-2.18M▲ 0%
48K▲ 102.2%
52K▲ 8.3%
-1.55M▼ 3075.0%
-1.37M▲ 11.4%
-819K▲ 40.2%
278K▲ 133.9%
322K▲ 15.8%
654K▲ 103.1%
544K▲ 0%
Gross Margin %-96%96.3%-6726.09%--350%96.86%98.77%48.95%40.63%
Gross Profit Growth %-179.25%102.2%8.33%-3075%11.44%40.22%133.94%15.83%103.11%-
Operating Expenses28.02M33.78M35.58M27.93M49.25M40.77M27.52M22.48M22.83M25.57M
OpEx % of Revenue-67558%65896.3%121430.43%-17424.79%9590.24%6895.71%1708.83%-
Selling, General & Admin6.93M11.19M9.16M7.8M20.56M17.45M11.78M10.03M9.98M10.63M
SG&A % of Revenue-22386%16957.41%33934.78%-7457.26%4104.18%3077.91%746.93%-
Research & Development21.09M22.63M24.59M20.12M30.07M24.38M15.74M12.45M12.85M14.95M
R&D % of Revenue-45258%45529.63%87495.65%-10417.52%5486.06%3817.79%961.9%-
Other Operating Expenses0000-1.37M-1.05M0000
Operating Income
-28.02M▲ 0%
-33.73M▼ 20.4%
-35.53M▼ 5.3%
-29.48M▲ 17.0%
-50.62M▼ 71.7%
-41.59M▲ 17.8%
-27.25M▲ 34.5%
-22.16M▲ 18.7%
-22.18M▼ 0.1%
-25.03M▲ 0%
Operating Margin %--67462%-65800%-128156.52%--17774.79%-9493.38%-6796.93%-1659.88%-1869.31%
Operating Income Growth %-20.16%-20.39%-5.34%17.04%-71.74%17.84%34.49%18.67%-0.08%-
EBITDA-25.84M-31.71M-33.57M-27.91M-49.25M-40.54M-26.88M-21.91M-21.86M-24.72M
EBITDA Margin %--63426%-62166.67%-121330.43%--17324.79%-9367.25%-6719.33%-1636.23%-1845.93%
EBITDA Growth %-22.07%-22.72%-5.86%16.87%-76.5%17.69%33.69%18.52%0.21%-15.13%
D&A (Non-Cash Add-back)2.18M2.02M1.96M1.57M1.37M1.05M362K253K316K313K
EBIT-27.75M-26.13M-35.31M-28.96M-49.79M-40.49M-28.04M-20.48M-22.38M-19.57M
Net Interest Income0-661K356K188K414K-306K241K448K271K-102K
Interest Income122K276K385K384K492K581K1.08M1.31M1.14M765K
Interest Expense0937K29K196K78K887K843K866K873K443K
Other Income/Expense205K7.61M225K324K758K219K-1.64M814K-1.08M-2.12M
Pretax Income
-27.81M▲ 0%
-26.13M▲ 6.1%
-35.31M▼ 35.1%
-29.15M▲ 17.4%
-49.87M▼ 71.1%
-41.37M▲ 17.0%
-28.89M▲ 30.2%
-21.34M▲ 26.1%
-23.25M▼ 9.0%
-27.11M▲ 0%
Pretax Margin %--52252%-65383.33%-126747.83%--17681.2%-10065.16%-6547.24%-1740.64%-2024.87%
Income Tax-205K0-94K00000-5K-13K
Effective Tax Rate %0.74%0%0.27%0%0%0%0%0%0.02%0.05%
Net Income
-27.81M▲ 0%
-26.13M▲ 6.1%
-35.31M▼ 35.1%
-29.15M▲ 17.4%
-49.87M▼ 71.1%
-41.24M▲ 17.3%
-28.32M▲ 31.3%
-20.89M▲ 26.2%
-22.58M▼ 8.1%
-26.75M▲ 0%
Net Margin %--52252%-65383.33%-126747.83%--17624.79%-9867.94%-6407.36%-1690.34%-1997.68%
Net Income Growth %-19.65%6.07%-35.14%17.43%-71.05%17.29%31.33%26.25%-8.11%-34.69%
Net Income (Continuing)-27.81M-26.13M-35.31M-29.15M-49.87M-41.37M-28.89M-21.34M-23.25M-20.24M
Discontinued Operations0000000000
Minority Interest000002.15M1.95M5.32M5.98M5.39M
EPS (Diluted)
-25.45▲ 0%
-19.74▲ 22.4%
-23.20▼ 17.5%
-12.80▲ 44.8%
-14.19▼ 10.9%
-10.24▲ 27.8%
-6.18▲ 39.6%
-3.99▲ 35.4%
-3.56▲ 10.8%
-0.29▲ 0%
EPS Growth %-8.85%22.44%-17.53%44.83%-10.86%27.84%39.65%35.44%10.78%6.99%
EPS (Basic)-25.45-19.74-23.20-12.80-14.19-10.24-6.18-3.99-3.56-
Diluted Shares Outstanding1.09M1.32M1.54M2.27M3.51M4.02M4.58M5.24M63.37M92.6M
Basic Shares Outstanding1.09M1.32M1.54M2.27M3.51M4.02M4.58M5.24M63.37M92.6M
Dividend Payout Ratio----------

PLUR Balance Sheet

Pluri Inc. (PLUR) balance sheet — assets, liabilities & shareholders' equity

Line itemJun'17Jun'18Jun'19Jun'20Jun'21Jun'22Jun'23Jun'24Jun'25TTM
Total Current Assets29.02M32.04M26.37M48.46M67.37M57.75M41.41M31.11M22.09M13.8M
Cash & Short-Term Investments26.11M29.9M23.7M46.34M64.95M55.02M40.17M29.98M20.61M4.69M
Cash Only4.71M8.82M4.11M8.82M31.24M9.77M5.36M6.78M5.89M4.69M
Short-Term Investments21.4M21.08M19.6M37.51M33.71M45.24M34.81M23.2M14.72M0
Accounts Receivable1.17M847K1.42M1.61M1.49M1.32M527K638K722K0
Days Sales Outstanding-6.18K9.6K25.55K-2.06K670.23714.33197.2581.37
Inventory00692K0000000
Days Inventory Outstanding--126.29K-------
Other Current Assets0021K67K598K1.01M269K262K525K9.11M
Total Non-Current Assets8.52M6.92M4.94M17.07M26.17M10.32M9.39M8.42M16.59M2.99M
Property, Plant & Equipment7.28M5.68M3.84M3.77M2.23M9.01M8.32M7.25M8.72M8.27M
Fixed Asset Turnover-0.01x0.01x0.01x-0.03x0.03x0.04x0.15x0.16x
Goodwill000000003.14M3.14M
Intangible Assets000000002.79M2.7M
Long-Term Investments403K383K398K12.65M000000
Other Non-Current Assets838K863K703K643K23.94M1.31M1.07M1.17M1.94M-5.51M
Total Assets
37.53M▲ 0%
38.96M▲ 3.8%
31.31M▼ 19.6%
65.53M▲ 109.3%
93.54M▲ 42.7%
68.06M▼ 27.2%
50.8M▼ 25.4%
39.53M▼ 22.2%
38.68M▼ 2.1%
16.79M▲ 0%
Asset Turnover-0.00x0.00x0.00x-0.00x0.01x0.01x0.03x0.04x
Asset Growth %-18.3%3.8%-19.64%109.3%42.74%-27.23%-25.37%-22.19%-2.14%-49.92%
Total Current Liabilities5.41M8.55M8.16M7.99M11.52M6.83M5.62M4.45M32.33M32.35M
Accounts Payable1.97M3.26M2.28M1.97M2.53M1.78M1.81M964K866K1.43M
Days Payables Outstanding329.62595.13K416.28K457.53672.99618.7373.49K87.97K463.48471.06
Short-Term Debt0001.02M000027.29M712K
Deferred Revenue (Current)0640K0126K40K112K151K124K341K823K
Other Current Liabilities687K946K03.02M1.2M1.51M873K702K859K31.59M
Current Ratio5.36x3.75x3.23x6.07x5.85x8.46x7.37x6.98x0.68x0.68x
Quick Ratio5.36x3.75x3.15x6.07x5.85x8.46x7.37x6.98x0.68x0.68x
Cash Conversion Cycle---280.39K-------389.69
Total Non-Current Liabilities1.87M1.91M1.33M1.44M24.87M29.05M29.88M29.66M7.22M6.54M
Long-Term Debt000023.85M21.68M23.53M24.03M06.14M
Capital Lease Obligations000565K100K6.5M5.75M5.03M6.1M17.77M
Deferred Tax Liabilities00000000415K1.22M
Other Non-Current Liabilities1.87M1.91M1.33M879K920K867K598K605K703K-3.97M
Total Liabilities7.28M10.45M9.49M9.43M36.39M35.88M35.5M34.11M39.55M7.46M
Total Debt0001.58M24.58M28.8M29.91M29.61M34.05M6.86M
Net Debt-4.71M-8.82M-4.11M-7.24M-6.66M19.03M24.55M22.83M28.16M2.17M
Debt / Equity---0.03x0.43x0.89x1.95x5.47x--0.74x
Debt / EBITDA----------0.28x
Net Debt / EBITDA----------0.09x
Interest Coverage--36.00x-1225.24x-150.39x-649.01x-46.89x-32.32x-25.59x-25.40x-44.17x
Total Equity
30.25M▲ 0%
28.51M▼ 5.8%
21.82M▼ 23.5%
56.1M▲ 157.1%
57.15M▲ 1.9%
32.19M▼ 43.7%
15.3M▼ 52.5%
5.42M▼ 64.6%
-865K▼ 116.0%
-9.21M▲ 0%
Equity Growth %-20.72%-5.77%-23.45%157.1%1.87%-43.68%-52.46%-64.61%-115.97%-9269.13%
Book Value per Share27.6821.5514.1524.6616.268.003.341.03-0.01-0.10
Total Shareholders' Equity30.25M28.51M21.82M56.1M57.15M30.04M13.36M96K-6.84M-14.61M
Common Stock1K1K1K0000000
Retained Earnings-189.57M-215.7M-251M-280.16M-330.02M-371.26M-399.58M-420.47M-443.06M-455.45M
Treasury Stock0000000000
Accumulated OCI2M-11.21M00000000
Minority Interest000002.15M1.95M5.32M5.98M5.39M

PLUR Cash Flow Statement

Pluri Inc. (PLUR) cash flow — operating, investing & free cash flow history

Line itemJun'17Jun'18Jun'19Jun'20Jun'21Jun'22Jun'23Jun'24Jun'25TTM
Cash from Operations-21.61M-21.38M-29.45M-26.37M-30.91M-36.5M-22.86M-18.02M-18.21M-18.21M
Operating CF Margin %--42760%-54542.59%-114647.83%--15598.72%-7964.11%-5527.91%-1363.1%-
Operating CF Growth %-16.68%1.07%-37.76%10.47%-17.22%-18.09%37.38%21.16%-1.05%-69.37%
Net Income-27.81M-26.13M-35.31M-29.15M-49.87M-41.37M-28.89M-21.34M-23.25M-26.75M
Depreciation & Amortization2.18M2.02M1.96M1.57M1.37M1.05M362K253K316K442K
Stock-Based Compensation3.66M6.55M5.15M2.56M13.97M8.91M3.98M2.62M2.14M3.44M
Deferred Taxes512K-7.57M000-15.18M-5.32M000
Other Non-Cash Items-14K5K-3K-11K86K15.18M5.32M473K-1.61M4.24M
Working Capital Changes-134K3.75M-1.25M-1.34M3.53M-5.09M1.69M-21K4.19M-1.01M
Change in Receivables1.19M978K-121K37K-256K-329K-336K438K-111K-160K
Change in Inventory-24.23M-21.93M0-789K0329K336K000
Change in Payables-701K1.21M-863K-291K578K-758K-22K-778K-235K-508K
Cash from Investing4.3M5.57M1.17M-30.46M-7.26M11.78M9.7M10.58M8.03M5.3M
Capital Expenditures-378K-342K-239K-270K-373K-280K-262K-323K-1.62M-1.69M
CapEx % of Revenue-684%442.59%1173.91%-119.66%91.29%99.08%121.11%-
Acquisitions30K-1.94M6K00000373K373K
Investments----------
Other Investing30K1.94M-6K-12.24M000002.93M
Cash from Financing15.8M19.92M23.58M60.87M61.4M7.5M8.02M8.84M9.53M12.38M
Debt Issued (Net)000024.45M-2.17M0000
Equity Issued (Net)1000K1000K1000K1000K1000K01000K91K1000K612K
Dividends Paid0000000000
Share Repurchases0000000000
Other Financing79K1.29M115K2.71M364K9.67M08.75M-47K2.8M
Net Change in Cash
-1.52M▲ 0%
4.11M▲ 371.4%
-4.7M▼ 214.3%
4.04M▲ 186.0%
22.61M▲ 459.2%
-20.43M▼ 190.3%
-5.16M▲ 74.8%
1.42M▲ 127.4%
-475K▼ 133.6%
-2.42M▲ 0%
Free Cash Flow
-21.99M▲ 0%
-21.72M▲ 1.2%
-29.69M▼ 36.7%
-26.64M▲ 10.3%
-31.28M▼ 17.4%
-36.78M▼ 17.6%
-23.12M▲ 37.1%
-18.34M▲ 20.7%
-19.83M▼ 8.1%
-22.01M▲ 0%
FCF Margin %--43444%-54985.19%-115821.74%--15718.38%-8055.4%-5626.99%-1484.21%-1643.99%
FCF Growth %-8.47%1.21%-36.69%10.28%-17.43%-17.57%37.14%20.65%-8.1%-24.89%
FCF per Share-20.12-16.42-19.26-11.71-8.90-9.14-5.05-3.50-0.31-0.31
FCF Conversion (FCF/Net Income)0.78x0.82x0.83x0.90x0.62x0.89x0.81x0.86x0.81x0.82x
Interest Paid0000000000
Taxes Paid-28K-27K-10K-10K000000

PLUR Key Ratios

Pluri Inc. (PLUR) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric201720182019202020212022202320242025TTM
Return on Equity (ROE)-81.32%-88.93%-140.31%-74.82%-88.06%-92.33%-119.28%-201.67%-992.66%701.98%
Return on Invested Capital (ROIC)-73.12%-111.86%-142.5%-66.41%-76.43%-61.34%-44.88%-48.81%-59.9%-59.9%
Gross Margin-96%96.3%-6726.09%--350%96.86%98.77%48.95%40.63%
Net Margin--52252%-65383.33%-126747.83%--17624.79%-9867.94%-6407.36%-1690.34%-1997.68%
Debt / Equity---0.03x0.43x0.89x1.95x5.47x--0.74x
Interest Coverage--36.00x-1225.24x-150.39x-649.01x-46.89x-32.32x-25.59x-25.40x-44.17x
FCF Conversion0.78x0.82x0.83x0.90x0.62x0.89x0.81x0.86x0.81x0.82x
Revenue Growth-100%-8%-57.41%-100%-22.65%13.59%309.82%97.49%

PLUR SEC Filings & Documents

Pluri Inc. (PLUR) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Mar 27, 2026·SEC

Material company update

Mar 2, 2026·SEC

Material company update

Jan 22, 2026·SEC

10-K Annual Reports

3
FY 2025

Sep 17, 2025·SEC

FY 2024

Sep 18, 2024·SEC

FY 2023

Sep 12, 2023·SEC

10-Q Quarterly Reports

6
FY 2026

Feb 12, 2026·SEC

FY 2025

Nov 12, 2025·SEC

FY 2025

May 13, 2025·SEC

PLUR Frequently Asked Questions

Pluri Inc. (PLUR) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Pluri Inc. (PLUR) reported $1.3M in revenue for fiscal year 2025.

Pluri Inc. (PLUR) grew revenue by 309.8% over the past year. This is strong growth.

Pluri Inc. (PLUR) reported a net loss of $26.7M for fiscal year 2025.

Dividend & Returns

Pluri Inc. (PLUR) has a return on equity (ROE) of -992.7%. Negative ROE indicates the company is unprofitable.

Pluri Inc. (PLUR) had negative free cash flow of $22.0M in fiscal year 2025, likely due to heavy capital investments.

Explore More PLUR

Pluri Inc. (PLUR) financial analysis — history, returns, DCA and operating performance tools

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screener
  • Themes
  • Market Valuation
  • Valuation
  • Compare
  • Total Return
  • DCA Calculator
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Follow @VCPScanner on X

Get weekly stock ideas — free

© 2026 VCP Scanner. All rights reserved.
About·Privacy Policy·Terms of Service
Not financial advice. Do your own research.